Patents by Inventor M. Wolfe

M. Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
    Publication number: 20070269531
    Abstract: A composition and method for prevention or treatment of cancer The composition comprises a non-steroid anti-inflammatory agent and at least one of nutritional supplement and/or chemotherapeutic agent.
    Type: Application
    Filed: May 13, 2005
    Publication date: November 22, 2007
    Applicant: Wyeth Patent Law Department
    Inventors: M. Wolfe, Richard Cotter, Alexandra Kropotova
  • Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
    Publication number: 20070173455
    Abstract: In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).
    Type: Application
    Filed: August 14, 2006
    Publication date: July 26, 2007
    Inventors: M. Wolfe, Chi-Chuan Tseng, Linda Neville
  • Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
    Publication number: 20070167374
    Abstract: In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).
    Type: Application
    Filed: August 15, 2006
    Publication date: July 19, 2007
    Inventors: M. Wolfe, Chi-Chuan Tseng, Linda Neville
  • Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
    Publication number: 20070167363
    Abstract: In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).
    Type: Application
    Filed: August 15, 2006
    Publication date: July 19, 2007
    Inventors: M. Wolfe, Chi-Chuan Tseng, Linda Neville